<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127504</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCID-3843</org_study_id>
    <nct_id>NCT00127504</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness</brief_title>
  <official_title>Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad del Valle, Guatemala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centers for Disease Control and Prevention</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether rifampin and/or azithromycin are effective
      in the treatment of river blindness (onchocerciasis).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mass treatment with ivermectin (Mectizan, Merck &amp; Co) is the mainstay of the current efforts
      to control onchocerciasis, but the drug is not lethal to adult Onchocerca volvulus parasites.
      Wolbachia, an endosymbiotic bacterium necessary for the fecundity of O. volvulus, can be
      eradicated with four-six week courses of doxycycline, but this cannot be implemented in
      current mass drug administration programs. The purpose of this study is to evaluate if a
      shorter course (five days) with antibiotics that could be used in children and potentially
      pregnant women would likewise be effective.

      Guatemalan patients with onchocercal nodules will be enrolled in an open label trial with
      four treatment groups: Group A (rifampin 20 mg/kg by mouth [po; maximum 600 mg/day]); B
      (azithromycin 12 mg/kg po [maximum 500 mg/day]); C (combination of rifampin 20 mg/kg po
      [maximum 600 mg/day] and azithromycin 12 mg/kg po [maximum 500 mg/day]); D (control group,
      multivitamin). At the end of the five day treatment course all participants will receive a
      single dose of ivermectin (150 mcg/kg).

      Nodulectomies will be performed 9 months after treatment and the O. volvulus will be analyzed
      by immunohistochemical staining specific for Wolbachia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date>May 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eliminating Wolbachia endobacteria present in O. volvulus worms after 9 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination of microfilaria in skin snips and histological examination of worms after 9 months</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Onchocerciasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and non-pregnant/non lactating females &gt;5 years of age

          -  One onchocercal nodule in an anatomical position where it can be easily removed
             surgically

        Exclusion Criteria:

          -  Pregnancy (based on urine pregnancy test)

          -  Breast-feeding

          -  Women taking oral contraceptives

          -  Allergy or other adverse reaction to either medication

          -  Use of other medications that might interact with rifampin

          -  Clinical evidence of liver disease (jaundice, swollen abdomen)

          -  Clinical evidence of chronic disease/alcoholism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef Amann, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CDC/NCID/DPD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad del Valle/MERTU</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guatemala</country>
  </location_countries>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2005</study_first_posted>
  <last_update_submitted>August 23, 2005</last_update_submitted>
  <last_update_submitted_qc>August 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2005</last_update_posted>
  <keyword>Onchocerciasis</keyword>
  <keyword>Wolbachia</keyword>
  <keyword>Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

